BioTech
Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after Covid delays
Federal regulators responsible for the safety of the U.S. drug supply are still struggling to get back to where they were in 2019, before the Covid-19
Matthew Perrone and Nicky Forster — Associated Press
September 5, 2024